Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver

Jr Alexander H.R., D. L. Bartlett, S. K. Libutti

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors or primary colangio- or hepatocellular carcinomas. A number of regional treatment strategies including infusional chemotherapy and local ablative therapy are under clinical development and attest to the difficulty in adequately treating this condition. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not gained widespread application. In light of the remarkable antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers confined to the liver and, with additional clinical development, will most likely be a more routinely considered option for patients with this condition.

Original languageEnglish (US)
Pages (from-to)416-424
Number of pages9
JournalOncologist
Volume5
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Perfusion
Liver
Melphalan
Neoplasms
Melanoma
Eye Neoplasms
Extremities
Therapeutics
Neuroendocrine Tumors
Liver Neoplasms
Sarcoma
Hepatocellular Carcinoma
Colorectal Neoplasms
Morbidity
Drug Therapy

Keywords

  • Isolation perfusion
  • Melphalan
  • Metastatic cancer of the liver
  • Tumor necrosis factor
  • Unresectable cancers

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. / Alexander H.R., Jr; Bartlett, D. L.; Libutti, S. K.

In: Oncologist, Vol. 5, No. 5, 2000, p. 416-424.

Research output: Contribution to journalArticle

@article{c9755141362e408dafd712eec9ba3e7a,
title = "Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver",
abstract = "Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors or primary colangio- or hepatocellular carcinomas. A number of regional treatment strategies including infusional chemotherapy and local ablative therapy are under clinical development and attest to the difficulty in adequately treating this condition. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not gained widespread application. In light of the remarkable antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers confined to the liver and, with additional clinical development, will most likely be a more routinely considered option for patients with this condition.",
keywords = "Isolation perfusion, Melphalan, Metastatic cancer of the liver, Tumor necrosis factor, Unresectable cancers",
author = "{Alexander H.R.}, Jr and Bartlett, {D. L.} and Libutti, {S. K.}",
year = "2000",
language = "English (US)",
volume = "5",
pages = "416--424",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver

AU - Alexander H.R., Jr

AU - Bartlett, D. L.

AU - Libutti, S. K.

PY - 2000

Y1 - 2000

N2 - Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors or primary colangio- or hepatocellular carcinomas. A number of regional treatment strategies including infusional chemotherapy and local ablative therapy are under clinical development and attest to the difficulty in adequately treating this condition. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not gained widespread application. In light of the remarkable antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers confined to the liver and, with additional clinical development, will most likely be a more routinely considered option for patients with this condition.

AB - Metastatic or primary unresectable cancers confined to the liver are the sole or life-limiting component of disease for many patients with colorectal cancer, ocular melanoma, neuroendocrine tumors or primary colangio- or hepatocellular carcinomas. A number of regional treatment strategies including infusional chemotherapy and local ablative therapy are under clinical development and attest to the difficulty in adequately treating this condition. Isolated hepatic perfusion (IHP) was first clinically applied over 40 years ago, but because of its technical complexity, the attendant potential morbidity, and the lack of documented efficacy, it has not gained widespread application. In light of the remarkable antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for unresectable liver cancers. IHP with TNF and melphalan can result in significant regression of advanced refractory cancers confined to the liver and, with additional clinical development, will most likely be a more routinely considered option for patients with this condition.

KW - Isolation perfusion

KW - Melphalan

KW - Metastatic cancer of the liver

KW - Tumor necrosis factor

KW - Unresectable cancers

UR - http://www.scopus.com/inward/record.url?scp=0033780015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033780015&partnerID=8YFLogxK

M3 - Article

C2 - 11040278

AN - SCOPUS:0033780015

VL - 5

SP - 416

EP - 424

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 5

ER -